United Therapeutics reported Phase 3 results showing ralinepag reduced the risk of clinical worsening by about 55% in pulmonary arterial hypertension, setting the company up to seek FDA approval this year. Management indicated an approval filing is planned with a potential commercial launch in 2027, and analysts expect the asset to compete in a crowded PAH landscape. The trial’s positive outcomes center on clinical worsening endpoints and supportive safety data that will be reviewed with regulators.